READ THE DESCRIPTION FOR EXTRA INFO:

Join Discord Server:
[ Ссылка ]

Channel Membership:
[ Ссылка ]

Donation Link:
[ Ссылка ]

Want to contact me?
Follow this: linktr.ee/kwxsoc

➤ Have hair loss questions? Send me an email at "kwkadvice@pm.me"
➤ For video 1-on-1 Consultation Booking: [ Ссылка ]

Microneedle Recommendations:
[ Ссылка ]
[ Ссылка ]

Support:
[ Ссылка ]



References:
開 拓 藥 業 有 限 公 司 ＊ KINTOR PHARMACEUTICAL LIMITED. (2024, February 2). CLINICAL TRIAL OF KX-826 AND MINOXIDIL COMBINATION THERAPY FOR THE TREATMENT OF MALE AGA RECEIVED CLEARANCE BY CHINA NMPA. www1.hkexnews.h. Retrieved February 5, 2024, from [ Ссылка ]

Alkilani, A. Z., McCrudden, M., & Donnelly, R. F. (2015). Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics, 7(4), 438–470. [ Ссылка ]

Pyrilutamide
[ Ссылка ]

IC50
[ Ссылка ]


Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA
[ Ссылка ]

Pyrilutamide is a potential first-in-class AR antagonist for topical dermatological use
[ Ссылка ]

开拓药业携四项临床研究亮相EADV 2023，KX-826口头报告获得广泛关注和认可
[ Ссылка ]

KINTOR BEGINS KX-826 PHASE 3 TRIAL FOR ANDROGENIC ALOPECIA
[ Ссылка ]

Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Androgenetic Alopecia Was Met
[ Ссылка ]


PSK3841 Human Trials info
[ Ссылка ]


A double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution at 5% administered twice daily over four weeks to healthy Caucasian males with androgenetic alopecia

[ Ссылка ]

RU-58841
[ Ссылка ]


A multi-centre, double-blind, randomised, vehicle-controlled study for a quantitative estimation of hair re-growth in male subjects with androgenetic alopecia treated over 6 month with two ethanolic PSK 3841 solutions (2.5% and 5%)
[ Ссылка ]


=====

#androgenicalopecia #malepatternbaldness #hairloss

свернуть